Dietary Supplement Revenue Growth
Dietary supplement revenue grew 19.1% year-over-year to $11.0 million in Q1 2026, driven primarily by continued growth of the e-commerce channel. Company expects supplement revenue to grow at a mid- to high single-digit rate for full-year 2026.
Salesforce Expansion and Commercial Investment
Expanded commercial organization with over 25 new sales hires in Q1, taking total sales personnel from just over 90 at the end of 2025 to approximately 120 planned for 2026. Management reports this expansion is substantially complete and intended to drive future practitioner recruitment and revenue growth.
Practitioner Training Pipeline
Trained more than 200 new practitioners in Q1, a 16.5% increase versus Q1 2025. Management notes new practitioner training is a leading indicator for future procedures and supplement sales, with typical contribution beginning about six months after training.
Maintained Full-Year Guidance
Management maintained 2026 guidance: full-year revenue above $190 million and adjusted EBITDA greater than $38 million, asserting confidence in a return to procedure revenue growth in the second half of 2026 despite the Q1 disruption.
Operational Recovery Actions at Asteria Health
Implemented measures to restore supply, including adding a second production shift at Asteria Health and using third-party pharmacy partners to fulfill demand. Asteria produced ~30% of shipped pellets in Q1 vs. >50% in Q4 2025; management expects Asteria supply continuity to be fully restored by the end of Q2 2026.
Positive Cash Flow and Liability Reduction
Generated operating cash flow of $3.9 million in Q1 2026 and held $5.3 million in cash and cash equivalents as of March 31, 2026. Company fully repaid remaining share repurchase liabilities in January 2026.